- Home
- CISS vs LGVN Comparison
CISS vs LGVN Comparison
Compare CISS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | LGVN |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 17.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | LGVN |
|---|---|---|
| Price | $0.22 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | ★ 1.6M | 464.4K |
| Earning Date | 11-18-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,613,149.00 | $1,437,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.53 |
| 52 Week High | $11.52 | $2.24 |
Technical Indicators
Market Signals| Indicator | CISS | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 16.90 | 35.78 |
| Support Level | $0.21 | $0.54 |
| Resistance Level | $0.24 | $0.63 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 1.43 | 10.20 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.